Correction: The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in  TNFAIP3  followed by mutations in  TBL1XR1  and  CREBBP

Hyunchul Jung; Hae Yong Yoo; Seung Ho Lee; Sohyun Shin; Sang Cheol Kim; Sejoon Lee; Je-Gun Joung; Jae-Yong Nam; Daeun Ryu; Jae Won Yun; Jung Kyoon Choi; Ambarnil Ghosh; Kyeong Kyu Kim; Seok Jin Kim; Won Seog Kim; Woong-Yang Park; Young-Hyeh Ko

doi:10.18632/oncotarget.26080

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP

PDF | How to cite

Oncotarget. 2018; 9:32882-32882. https://doi.org/10.18632/oncotarget.26080

Metrics: PDF 1536 views | ?

Hyunchul Jung^1,4,*, Hae Yong Yoo^2,*, Seung Ho Lee^2,*, Sohyun Shin³, Sang Cheol Kim⁴, Sejoon Lee⁴, Je-Gun Joung⁴, Jae-Yong Nam^2,4, Daeun Ryu^2,4, Jae Won Yun^4,5, Jung Kyoon Choi¹, Ambarnil Ghosh⁵, Kyeong Kyu Kim⁵, Seok Jin Kim⁶, Won Seog Kim⁶, Woong-Yang Park¹ and Young Hyeh Ko³

¹ Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea
² Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea
³ Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
⁴ Samsung Genome Institute, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea
⁵ Department of Molecular Cell Biology, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea
⁶ Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
^* These authors have contributed equally to this work

Published: August 28, 2018

This article has been corrected: The correct order of author affiliations is given below:

Original article: Oncotarget. 2017; 8:17038-17049. DOI: https://doi.org/10.18632/oncotarget.14928.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26080

Publication Alerts

Corrections:

Correction: The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP